WO2001028535A3 - Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate - Google Patents
Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate Download PDFInfo
- Publication number
- WO2001028535A3 WO2001028535A3 PCT/EP2000/010306 EP0010306W WO0128535A3 WO 2001028535 A3 WO2001028535 A3 WO 2001028535A3 EP 0010306 W EP0010306 W EP 0010306W WO 0128535 A3 WO0128535 A3 WO 0128535A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salmeterol
- combination
- pharmaceutical formulations
- fluticasone propionate
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU13858/01A AU1385801A (en) | 1999-10-21 | 2000-10-19 | Pharmaceutical formulations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9924992.2A GB9924992D0 (en) | 1999-10-21 | 1999-10-21 | Pharmaceutical aerosol formulations |
GB9924992.2 | 1999-10-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001028535A2 WO2001028535A2 (en) | 2001-04-26 |
WO2001028535A3 true WO2001028535A3 (en) | 2002-01-10 |
Family
ID=10863173
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/010306 WO2001028535A2 (en) | 1999-10-21 | 2000-10-19 | Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate |
PCT/EP2000/010305 WO2001028514A1 (en) | 1999-10-21 | 2000-10-19 | Pharmaceutical aerosol formulations comprising s-salmeterol |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/010305 WO2001028514A1 (en) | 1999-10-21 | 2000-10-19 | Pharmaceutical aerosol formulations comprising s-salmeterol |
Country Status (3)
Country | Link |
---|---|
AU (2) | AU1141101A (en) |
GB (1) | GB9924992D0 (en) |
WO (2) | WO2001028535A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
US9198885B2 (en) | 2005-07-14 | 2015-12-01 | Neothetics, Inc. | Lipolytic methods for regional adiposity comprising salmeterol or formoterol |
US9597531B2 (en) | 2010-11-24 | 2017-03-21 | Neothetics, Inc. | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR030516A1 (en) * | 2000-08-31 | 2003-08-20 | Glaxo Group Ltd | USE OF A COMBINATION OF SALMETEROL AND FLUTICASONA |
GB0021927D0 (en) * | 2000-09-07 | 2000-10-25 | Glaxo Group Ltd | Use of pharmaceutical combination |
GB0106031D0 (en) * | 2001-03-12 | 2001-05-02 | Glaxo Group Ltd | Use |
GB0124523D0 (en) * | 2001-10-12 | 2001-12-05 | Glaxo Group Ltd | Pharmaceutical combination |
AU2004241746A1 (en) * | 2003-05-22 | 2004-12-02 | Nycomed Gmbh | Salmeterol and ciclesonide combination |
TR201000685A2 (en) * | 2010-01-29 | 2011-08-22 | Bi̇lgi̇ç Mahmut | Pharmaceutical preparations containing salmeterol and fluticasone. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993011743A1 (en) * | 1991-12-12 | 1993-06-24 | Glaxo Group Limited | Medicaments |
WO1996032150A1 (en) * | 1995-04-14 | 1996-10-17 | Glaxo Wellcome Inc. | Metered dose inhaler for salmeterol |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6254882B1 (en) * | 1997-09-16 | 2001-07-03 | Sepracor Inc. | Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol |
-
1999
- 1999-10-21 GB GBGB9924992.2A patent/GB9924992D0/en not_active Ceased
-
2000
- 2000-10-19 WO PCT/EP2000/010306 patent/WO2001028535A2/en active Application Filing
- 2000-10-19 WO PCT/EP2000/010305 patent/WO2001028514A1/en active Application Filing
- 2000-10-19 AU AU11411/01A patent/AU1141101A/en not_active Abandoned
- 2000-10-19 AU AU13858/01A patent/AU1385801A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993011743A1 (en) * | 1991-12-12 | 1993-06-24 | Glaxo Group Limited | Medicaments |
WO1996032150A1 (en) * | 1995-04-14 | 1996-10-17 | Glaxo Wellcome Inc. | Metered dose inhaler for salmeterol |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9198885B2 (en) | 2005-07-14 | 2015-12-01 | Neothetics, Inc. | Lipolytic methods for regional adiposity comprising salmeterol or formoterol |
US9370498B2 (en) | 2005-07-14 | 2016-06-21 | Neothetics, Inc. | Methods of using lipolytic formulations for regional adipose tissue treatment |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
US9597531B2 (en) | 2010-11-24 | 2017-03-21 | Neothetics, Inc. | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
Also Published As
Publication number | Publication date |
---|---|
AU1141101A (en) | 2001-04-30 |
GB9924992D0 (en) | 1999-12-22 |
WO2001028514A1 (en) | 2001-04-26 |
AU1385801A (en) | 2001-04-30 |
WO2001028535A2 (en) | 2001-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW329387B (en) | Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate | |
EP1600168A3 (en) | A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder | |
IL143512A (en) | Azabicycloalkanes, pharmaceutical compositions comprising same and use thereof for the manufacture of medicaments for the prevention or treatment of infection by immunodeficiency virus | |
IL195723A (en) | Use of p53 inhibitors for the preparation of medicament | |
WO2003032928A3 (en) | Therapeutic composition and use | |
HK1042825A1 (en) | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs | |
GB9918559D0 (en) | Novel pharmaceutical formulation | |
WO2002069979A3 (en) | Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate | |
AU6083899A (en) | Combination of c1-inh and lung surfactant for the treatment of respiratory disorders | |
WO2001076601A3 (en) | Pharmaceutical compositions comprising salmeterol and ipratropium | |
WO2001028535A3 (en) | Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate | |
GB9103764D0 (en) | Compositions | |
AU7862401A (en) | Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer | |
MXPA03001752A (en) | Pharmaceutical formulation of salmeterol and fluticasone propionate. | |
AUPQ344799A0 (en) | Treatment of respiratory diseases and infections | |
WO2005044186A3 (en) | Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same | |
AU3598299A (en) | Improved compositions for inhalation | |
WO2003018535A3 (en) | Novel aminobenzoephenones | |
AU2002325169A1 (en) | Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases | |
HK1075654A1 (en) | Hyperforin derivatives, the use thereof and formulations containing them | |
AU2001262741A1 (en) | Medicines for the prevention and treatment of neurodegenerative diseases | |
AU5611701A (en) | Agent for the diagnosis and therapy of viral diseases | |
AU2003255111A1 (en) | The use of n-acetyl-d-glucosamine for preparing medicines for urogenital tract infection's treatment and prevention | |
AU2908501A (en) | Combination therapy for the treatment of inflammatory and respiratory diseases | |
AU2728301A (en) | Combination therapy for the treatment of inflammatory and respiratory diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |